Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 131

1.

Cervical cancer screening in Belgium and overscreening of adolescents.

Van Kerrebroeck H, Makar A.

Eur J Cancer Prev. 2016 Mar;25(2):142-8. doi: 10.1097/CEJ.0000000000000155.

PMID:
25812038
2.

The influence of type-specific human papillomavirus infections on the detection of cervical precancer and cancer: A population-based study of opportunistic cervical screening in the United States.

Wheeler CM, Hunt WC, Cuzick J, Langsfeld E, Robertson M, Castle PE; New Mexico HPV Pap Registry Steering Committee.

Int J Cancer. 2014 Aug 1;135(3):624-34. doi: 10.1002/ijc.28605. Epub 2014 Apr 15.

3.

Design and methods of the evaluation of an HPV-based cervical cancer screening strategy in Mexico: The Morelos HPV Study.

Flores Y, Shah K, Lazcano E, Hernández M, Bishai D, Ferris DG, Lörincz A, Hernández P, Salmerón J; Morelos HPV Study Collaborators.

Salud Publica Mex. 2002 Jul-Aug;44(4):335-44.

PMID:
12216521
4.

The HPV test has similar sensitivity but more overdiagnosis than the Pap test--a randomised health services study on cervical cancer screening in Finland.

Malila N, Leinonen M, Kotaniemi-Talonen L, Laurila P, Tarkkanen J, Hakama M.

Int J Cancer. 2013 May 1;132(9):2141-7. doi: 10.1002/ijc.27850. Epub 2012 Oct 12.

5.

Clinical human papillomavirus detection forecasts cervical cancer risk in women over 18 years of follow-up.

Castle PE, Glass AG, Rush BB, Scott DR, Wentzensen N, Gage JC, Buckland J, Rydzak G, Lorincz AT, Wacholder S.

J Clin Oncol. 2012 Sep 1;30(25):3044-50. doi: 10.1200/JCO.2011.38.8389. Epub 2012 Jul 30.

7.

Identifying women with cervical neoplasia: using human papillomavirus DNA testing for equivocal Papanicolaou results.

Manos MM, Kinney WK, Hurley LB, Sherman ME, Shieh-Ngai J, Kurman RJ, Ransley JE, Fetterman BJ, Hartinger JS, McIntosh KM, Pawlick GF, Hiatt RA.

JAMA. 1999 May 5;281(17):1605-10.

PMID:
10235153
8.

[Prevalence of human papillomavirus infection in Slovenian women with repeated Pap II smears].

Salimović-Besić I, Bokal EV, Poljak M, Kocjan B.

Med Arh. 2005;59(1):47-51. Bosnian.

PMID:
15822686
9.

Screening trial of human papillomavirus for early detection of cervical cancer in Santiago, Chile.

Ferreccio C, Barriga MI, Lagos M, Ibáñez C, Poggi H, González F, Terrazas S, Katki HA, Núñez F, Cartagena J, Van De Wyngard V, Viñales D, Brañes J.

Int J Cancer. 2013 Feb 15;132(4):916-23. doi: 10.1002/ijc.27662. Epub 2012 Jun 26. Erratum in: Int J Cancer. 2013 Jul 15;133(2):E1.

10.

Use of a high-risk human papillomavirus DNA test as the primary test in a cervical cancer screening programme: a population-based cohort study.

Zorzi M, Del Mistro A, Farruggio A, de'Bartolomeis L, Frayle-Salamanca H, Baboci L, Bertazzo A, Cocco P, Fedato C, Gennaro M, Marchi N, Penon MG, Cogo C, Ferro A.

BJOG. 2013 Sep;120(10):1260-7; discussion 1267-8. doi: 10.1111/1471-0528.12272. Epub 2013 Jun 21.

11.

Comparison of HPV-based assays with Papanicolaou smears for cervical cancer screening in Morelos State, Mexico.

Salmerón J, Lazcano-Ponce E, Lorincz A, Hernández M, Hernández P, Leyva A, Uribe M, Manzanares H, Antunez A, Carmona E, Ronnett BM, Sherman ME, Bishai D, Ferris D, Flores Y, Yunes E, Shah KV.

Cancer Causes Control. 2003 Aug;14(6):505-12.

PMID:
12948281
12.

Updated guidelines for papanicolaou tests, colposcopy, and human papillomavirus testing in adolescents.

Widdice LE, Moscicki AB.

J Adolesc Health. 2008 Oct;43(4 Suppl):S41-51. doi: 10.1016/j.jadohealth.2008.04.007. Epub 2008 Jul 23. Review.

13.

Evaluation of human papillomavirus testing in primary screening for cervical abnormalities: comparison of sensitivity, specificity, and frequency of referral.

Kulasingam SL, Hughes JP, Kiviat NB, Mao C, Weiss NS, Kuypers JM, Koutsky LA.

JAMA. 2002 Oct 9;288(14):1749-57.

PMID:
12365959
14.

Prevalence of high-risk human papillomavirus in women with abnormal and normal vaginal ThinPrep Papanicolaou cytology.

Bansal M, Zhao C.

J Low Genit Tract Dis. 2011 Apr;15(2):105-9. doi: 10.1097/LGT.0b013e3181f41ee4.

PMID:
21317806
15.

HPV testing for cervical cancer screening appears more cost-effective than Papanicolau cytology in Mexico.

Flores YN, Bishai DM, Lorincz A, Shah KV, Lazcano-Ponce E, Hernández M, Granados-García V, Pérez R, Salmerón J.

Cancer Causes Control. 2011 Feb;22(2):261-72. doi: 10.1007/s10552-010-9694-3. Epub 2010 Dec 18.

16.

Cervical smears and human papillomavirus typing in sex workers.

Mak R, Van Renterghem L, Cuvelier C.

Sex Transm Infect. 2004 Apr;80(2):118-20.

17.

Knowledge, Attitudes and Practices of Sudanese Women Regarding the Pap Smear Test and Cervical Cancer.

Almobarak AO, Elbadawi AA, Elmadhoun WM, Elhoweris MH, Ahmed MH.

Asian Pac J Cancer Prev. 2016;17(2):625-30.

18.

[Human Papilloma Virus (HPV), cervical cancer incidence and screening uptake: differences among Northern, Central and Southern Italy].

Giorgi Rossi P, Chini F, Borgia P, Guasticchi G, Carozzi FM, Confortini M, Angeloni C, Buzzoni C, Buonaguro FM; Gruppo di lavoro HPV Prevalenza.

Epidemiol Prev. 2012 Mar-Apr;36(2):108-19. Review. Italian.

PMID:
22706361
19.

Five-Year Cervical (Pre)Cancer Risk of Women Screened by HPV and Cytology Testing.

Uijterwaal MH, Polman NJ, Van Kemenade FJ, Van Den Haselkamp S, Witte BI, Rijkaart D, Berkhof J, Snijders PJ, Meijer CJ.

Cancer Prev Res (Phila). 2015 Jun;8(6):502-8. doi: 10.1158/1940-6207.CAPR-14-0409. Epub 2015 Mar 16.

20.

Persistent human papillomavirus infection as a predictor of cervical intraepithelial neoplasia.

Schlecht NF, Kulaga S, Robitaille J, Ferreira S, Santos M, Miyamura RA, Duarte-Franco E, Rohan TE, Ferenczy A, Villa LL, Franco EL.

JAMA. 2001 Dec 26;286(24):3106-14.

PMID:
11754676

Supplemental Content

Support Center